{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:13:59Z","timestamp":1788545639005,"version":"build-2803163510"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To describe the clinical, immunological, virological and safety outcomes observed during anti\u2013IL-17 therapy in patients living with HIV who had cutaneous psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Four patients living with HIV who had cutaneous psoriasis and were treated with anti\u2013IL-17 agents were included in this case series. Psoriasis Area Severity Index (PASI) scores, CD4 cell counts, HIV RNA levels, treatment duration and adverse events were obtained from medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three patients received secukinumab and one received ixekizumab. Psoriasis improved in all four patients. CD4 cell counts remained stable or increased, while HIV RNA levels remained suppressed or declined following antiretroviral therapy. No adverse events were observed during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti\u2013IL-17 therapy was associated with clinical improvement without observed deterioration in immunological or virological parameters in this small case series. Larger prospective studies are required before conclusions regarding safety can be drawn.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624261485266","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:00:22Z","timestamp":1788418822000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti\u2013IL-17 therapy in people living with HIV who have cutaneous psoriasis: A four-patient case series"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8998-2138","authenticated-orcid":false,"given":"Melike Merve","family":"G\u00fc\u00e7l\u00fc","sequence":"first","affiliation":[{"name":"Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Asl\u0131","family":"Hapa","sequence":"additional","affiliation":[{"name":"Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Elif","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[{"name":"Sanko Universitesi"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12359"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70101-8"},{"key":"e_1_3_6_4_2","first-page":"646","article-title":"Secukinumab in an HIV-positive patient with psoriasis","volume":"17","author":"Di Lernia V","year":"2019","unstructured":"Di Lernia V, Casanova DM, Garlassi E. Secukinumab in an HIV-positive patient with psoriasis. JDDG - Journal of the German Society of Dermatology 2019; 17: 646\u2013648. https:\/\/doi.org\/10.1111\/ddg.13851","journal-title":"JDDG - Journal of the German Society of Dermatology"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000508781"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13895"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15610"},{"key":"e_1_3_6_8_2","first-page":"e415","article-title":"Secukinumab treatment for a psoriasis patient co-infected with HIV and latent tuberculosis: a case report","volume":"49","author":"Qin H","year":"2022","unstructured":"Qin H, Lu J, Yi X, et al. Secukinumab treatment for a psoriasis patient co-infected with HIV and latent tuberculosis: a case report. J Dermatol (Tokyo) 2022; 49: e415\u2013e416. https:\/\/doi.org\/10.1111\/1346-8138.16494","journal-title":"J Dermatol (Tokyo)"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S395348"},{"issue":"3","key":"e_1_3_6_10_2","first-page":"195","article-title":"HIV positive patient treated with ixekizumab","volume":"173","author":"Bernardini N","year":"2022","unstructured":"Bernardini N, Skroza N, Tolino E, et al. HIV positive patient treated with ixekizumab. Clin Ter 2022; 173(3): 195\u2013197. https:\/\/doi.org\/10.7417\/CT.2022.2416","journal-title":"Clin Ter"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omad066"},{"key":"e_1_3_6_12_2","first-page":"e71970","article-title":"Successful biological treatment of a patient with psoriasis and HIV","volume":"16","author":"Ortegon Blanco AE","year":"2024","unstructured":"Ortegon Blanco AE, Alonzo Canul ME. Successful biological treatment of a patient with psoriasis and HIV. Cureus 2024; 16: e71970. https:\/\/doi.org\/10.7759\/cureus.71970","journal-title":"Cureus"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-024-00675-8"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_619_24"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/2475530320954279"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200439"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03395-1"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14436"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2020.96155"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624261485266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624261485266","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624261485266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:53:17Z","timestamp":1788544397000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624261485266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":18,"alternative-id":["10.1177\/09564624261485266"],"URL":"https:\/\/doi.org\/10.1177\/09564624261485266","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"09564624261485266"}}